Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab...
Drug: Cisplatin Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles ... Drug: Cisplatin Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles ... Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab ... Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab ...https://clinicaltrials.gov/ct2/show/record/NCT00620971
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with...
cisplatin), the cumulative dose intensity of cisplatin (,200 vs. ≤200 mg/m2), and the pre-treatment plasma levels of EBV DNA ... In the group receiving cisplatin every three weeks, 88.9 % of the patients completed two cycles of cisplatin, and only 6.2 % of ... We did not provide a suggestive cisplatin delivery regimen or the optimal cumulative cisplatin dose in this study. Further ... of 80-100 mg/m2 cisplatin every 3 weeks or of 30-40 mg/m2 IV cisplatin weekly. Among all of the 491 patients, 14 (2.9 %) had a ...https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1964-8
Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for...
This study is investigating the efficacy and safety of cisplatin combined with gimeracil/oteracil/tegafur [S-1] compared with ... Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for ... Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for ...http://adisinsight.springer.com/trials/700215792?error=cookies_not_supported&code=c4193460-43d4-4f26-aafe-7878c5bd2382
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Tabular...
Drug: Vinorelbine followed by Cisplatin Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/ ... The proposed study is a multi-center open label phase II study of the chemotherapy doublets cisplatin/vinorelbine and cisplatin ... This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based ... Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703). ...https://clinicaltrials.gov/ct2/show/record/NCT00545948
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression ...
Chk1 and Chk2 phosphorylation by cisplatin treatment. The exact mechanism of how initial cisplatin lesions are recognized and ... Overexpression of ERCC1-XPF resulted in repair of cisplatin induced ICLs and decreased cisplatin sensitivity suggesting that ... treated with cisplatin for 1 h and investigated for gH2AX formation as a marker for damage related to cisplatin ICLs 24 and 48 ... Similar data were obtained for cisplatin in ERCC1 mutated UV96 hamster cells . In renal cells cisplatin lead to sustained ...https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-248
Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer
Cisplatin-based chemotherapy is the standard therapy used for the treatment of several types of cancer. However, its efficacy ... Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer. * ... To date, little is known about the RNA expression changes in cisplatin-resistant cancers. Identification of the RNAs related to ... A signal transduction network was established to identify the core genes in regulating cancer cell cisplatin resistance. A ...https://spandidos-publications.com/or/30/2/596
Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. - Semantic Scholar
Cisplatin had a peak in vitro scleral permeability constant of 8.3+/-1.2 x 10(-6) and 20.1+/-1.8 x 10(-6) cm/s, delivered in ... Cisplatin in either a collagen matrix vehicle or a control balanced salt solution (BSS) vehicle was applied to human sclera ... The amount of cisplatin that diffused across the sclera was measured in hourly samples for 24 h using atomic absorption ... Subconjunctival injection of cisplatin in the collagen matrix vehicle achieved 3.3+/-0.1 microg/ml in the vitreous humor at 1.5 ...https://www.semanticscholar.org/paper/Transscleral-permeability-and-intraocular-concentr-Gilbert-Simpson/9b4156e1b5058dd32d36142212bfe98197f8d3e9
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel - Full Text View -...
No perceived or actual clinical risk of cisplatin induced toxicity that exceeds the clinical benefit of using cisplatin therapy ... Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel. The safety and ... Drug Information available for: Cisplatin Paclitaxel Genetic and Rare Diseases Information Center resources: Ovarian Cancer ... The MTD intensity of cisplatin is defined as the least saline hydration volume at which no more than 1 of 6 patients experience ...https://clinicaltrials.gov/ct2/show/NCT00003569
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in...
Drug: Cisplatin 1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium ... Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 ... Experimental: Treatment B: Cisplatin-Gemcitabine-Copanlisib Treatment consists of repetitive 21 day cycles for a maximum of 8 ... Subjects, at least 18 years of age, with advanced or refractory solid tumors in whom gemcitabine (Treatment A) or cisplatin ...https://clinicaltrials.gov/ct2/show/record/NCT01460537
Long-Term In vivo Effects of Cisplatin on γ-H2AX Foci Signaling in Peripheral Lymphocytes of Tumor Patients After Irradiation |...
... cisplatin mono, cisplatin/navelbine, cisplatin/etoposide), and (e) time of blood sampling from cisplatin exposure. A repeated ... b) Cisplatin resistance in tumors can be evaluated by IRIFF. (c) Cisplatin-dependent IRIFF in lymphocytes and tumor cells after ... Although the cisplatin effect on γ-H2AX foci remained relatively constant during the first 3 to 4 days after cisplatin exposure ... Although the effect of cisplatin dose (P = 0.66; F-test) and the number of the cisplatin application (P = 0.49; F-test) were ...http://clincancerres.aacrjournals.org/content/15/8/2927
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Full Text...
Drug: Vinorelbine followed by Cisplatin Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/ ... Drug: Vinorelbine followed by Cisplatin Drug: Pemetrexed followed by Cisplatin Phase 2 ... This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based ... Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703). ...https://clinicaltrials.gov/show/NCT00545948
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic...
Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin. Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin ... Drug Information available for: Fluorouracil Cisplatin Docetaxel Bevacizumab Genetic and Rare Diseases Information Center ... Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic ... Patients may not have received prior docetaxel or cisplatin, or bevacizumab or any other novel biologic anti-angiogenic agent. ...https://clinicaltrials.gov/ct2/show/NCT00390416
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be...
Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 ... Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be ... Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be ... Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either ...https://clinicaltrials.gov/ct2/show/record/NCT00445861
Cisplatin-resistant human ovarian cancer SK-OV cells, which are retaining 25-fold higher levels of GSH than murine fibroblasts ... The treatment of alkylating cytotoxic drug cisplatin is often limited by high incidence rate of resistance. In the present ... Nrf2-deficient murine embryonic fibroblasts showed increased cell death, cytotoxicity, and apoptosis in response to cisplatin ... with Nrf2 siRNA into SK-OV cells resulted in severe degree of GSH depletion and exacerbated cytotoxicity following cisplatin ...http://cancerres.aacrjournals.org/content/68/9_Supplement/705
Cisplatin - Wikipedia
Cisplatin: The Invention of an Anticancer Drug by Andri Smith Anti-cancer Agents: A treatment of Cisplatin and their analogues ... It is suggested that an antibody reacting with a cisplatin-red-cell membrane is responsible for hemolysis. Cisplatin interferes ... cisplatin is used in Auger therapy. Often, medical practitioners and researchers must be careful about how long cisplatin ... so it is not primarily due to the cisplatin. Hemolytic anemia can be developed after several courses of cisplatin. ...https://en.wikipedia.org/wiki/Cisplatin
Cisplatin - National Cancer Institute
This page contains brief information about cisplatin and a collection of links to more information about the use of this drug, ... Cisplatin is approved to be used alone or with other drugs to treat:. *Bladder cancer that cannot be treated with surgery or ... More About Cisplatin. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ... MedlinePlus Information on Cisplatin - A lay language summary of important information about this drug that may include the ...https://www.cancer.gov/about-cancer/treatment/drugs/cisplatin
Cisplatin - Wikipedia
Cisplatin: The Invention of an Anticancer Drug by Andri Smith. *Anti-cancer Agents: A treatment of Cisplatin and their ... Cisplatin resistanceEdit. Cisplatin combination chemotherapy is the cornerstone of treatment of many cancers. Initial platinum ... "Cisplatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ British national formulary: BNF 69 (69 ed ... Cisplatin". Annals of Internal Medicine. 100 (5): 704-13. doi:10.7326/0003-4819-100-5-704. PMID 6370067.. ...https://en.m.wikipedia.org/wiki/Cisplatin
P&U Cisplatin - Drugs.com
A list of US medications equivalent to P&U Cisplatin is available on the Drugs.com website. ... P&U Cisplatin is a medicine available in a number of countries worldwide. ... Ingredient matches for P&U Cisplatin. Cisplatin. Cisplatin is reported as an ingredient of P&U Cisplatin in the following ... P&U Cisplatin. P&U Cisplatin may be available in the countries listed below. ...https://www.drugs.com/international/p-u-cisplatin.html
Cisplatin - Drug Information - Chemocare
Cisplatin (Platinol, CDDP) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatent ... If cisplatin escapes from the vein it can cause tissue damage. The nurse or doctor who gives cisplatin must be carefully ... Cisplatin side effects will improve after therapy is complete.. *Cisplatin side effects may be quite manageable. There are many ... How Cisplatin Is Given:. *Cisplatin is administered through a vein (intravenously or IV) as an infusion. ...http://chemocare.com/chemotherapy/drug-info/cisplatin.aspx
The Cisplatin-Induced Cellular Injury Response | SpringerLink
Treatment of cells with clinically relevant exposures to cisplatin (DDP) activates an injury response that eventually induces ... Cisplatin: A preclinical overview. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin: Current Status and New Developments ... Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor ... Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp ...https://link.springer.com/chapter/10.1007/978-1-4899-0218-4_25
Cisplatin - Information and support - Macmillan Cancer Support
What is cisplatin?. Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, and non-small ... How cisplatin is given. You usually have cisplatin in the chemotherapy day unit or during a stay in hospital. A chemotherapy ... Each cycle of cisplatin usually takes 21 days (three weeks). You usually have the cisplatin on the first day of the cycle. But ... Possible side effects of cisplatin. We explain the most common side effects of cisplatin here. But we don't include all the ...https://www.macmillan.org.uk/information-and-support/lung-cancer/small-cell-lung-cancer/treating/chemotherapy/drugs-and-combination-regimens/individual-drugs/cisplatin.html
Abiplatin (Cisplatin) Teva
Injectable; Injection; Cisplatin 0.5 mg / ml*Injectable; Injection; Cisplatin 1 mg / ml. ...http://drugs-about.com/drugs-a/abiplatin.html
Chemotherapeutic Synergy: Cisplatin | GreenMedInfo | Keyword
The combined use of 1,25(OH)2D3 and cisplatin may be used as a strategy to overcome resistance to cisplatin and dose ... Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.Jul 31, 2017. ... Curcumin potentiates Cisplatin-induced proliferation inhibitory effect and apoptosis in A549 and Cisplatin resistant lung ... Additional Keywords : Chemotherapeutic Synergy: Cisplatin, Chemotherapy-Induced Toxicity: Cisplatin, Inflammation, Lipid ...http://www.greenmedinfo.com/keyword/chemotherapeutic-synergy-cisplatin
Cisplatin (IARC Summary & Evaluation, Volume 26, 1981)
CISPLATIN. VOL.: 26 (1981) (p. 151) 5. Summary of Data Reported and Evaluation. 5.1 Experimental data. Cisplatin was tested by ... See Also: Toxicological Abbreviations Cisplatin (PIM 132) Cisplatin (UKPID) ... Cisplatin has been used since the 1970s primarily in the treatment of testicular and ovarian cancer, often in combination with ... Cisplatin is a mutagen in bacterial and cultured mammalian cells. It also induces chromosomal aberrations in various cells in ...http://www.inchem.org/documents/iarc/vol26/cisplatin.html
Cisplatin & fluorouracil - Information and support - Macmillan Cancer Support
If you or someone close to you has been diagnosed with cancer, you're not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other people's experiences.https://www.macmillan.org.uk/information-and-support/lung-cancer/small-cell-lung-cancer/treating/chemotherapy/drugs-and-combination-regimens/combination-chemotherapy/docetaxel-and-cisplatin.html